Look back at pharma news in the week to August 7, 2020

9 August 2020

By Barbara Obstoj-Cardwell. Editor

Last week’s notable regulatory news included Germany’s MorphoSys and US partner Incyte gaining approval from the US Food and Drug Administration for their B-cell lymphoma drug Monjuvi (tafasitamab). Also, GlaxoSmithKline’s return to the oncology sector was rewarded last week with FDA approval for its Blenrep (belantamab mafodotin), the first ever anti-BCMA agent. Among research developments, Immunic released positive Phase II data for its IMU-838 in the treatment of relapsing-remitting multiple sclerosis (RRMA), and Denmark’s Lundbeck announced the discontinuation of its Phase II study of Lu AF11167 in schizophrenia. Deal-making featured a potential $2 billion agreement for Biogen to acquire rights to a Parkinson’s disease program from Denali Therapeutics

Tafasitamab receives 2L label and clean safety language

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK